2023 World Conference on Lung Cancer (Posters)-EP12.01. An Observational Study Analyzing Progression Free Survival of Patients With EGFR Mutant NSCLC Treated with Osimertinib in South Carolina

EP12.01. An Observational Study Analyzing Progression Free Survival of Patients With EGFR Mutant NSCLC Treated with Osimertinib in South Carolina - PDF(Slides)

Back to course

Pdf Summary

An observational study in South Carolina analyzed the progression-free survival (PFS) of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) treated with Osimertinib. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has shown superiority over other first-generation inhibitors in terms of survival outcomes. It is now recommended as the first-line treatment for NSCLC patients with exon 19 deletion and exon 21 L858R mutations, as well as for subsequent therapy post-disease progression on other tyrosine kinase inhibitors.<br /><br />The study focused on specific exon mutations and concurrent programmed death ligand (PDL) mutations. It found no significant difference in PFS outcomes on Osimertinib between patients with exon 19 deletion and exon 21 L858R mutations. However, there was a statistically significant decrease in PFS for patients with exon 20 mutations compared to other studied mutations.<br /><br />Additionally, patients with coexisting EGFR and PDL mutations had a median PFS of 6 months on Osimertinib. These findings highlight the importance of considering individual genetic profiles in determining effective therapies, paving the way for further advancements in personalized medicine.<br /><br />Overall, Osimertinib has revolutionized the treatment of EGFR mutant NSCLC, demonstrating its potency as a third-generation EGFR inhibitor and its impact on treatment strategies. This study contributes to the understanding of different exon mutations and their effects on PFS, emphasizing the need for alternative treatments for patients with exon 20 mutations. The findings also suggest the potential for using pembrolizumab for patients with both EGFR and PDL mutations, indicating future research and treatment innovations.

Asset Subtitle

Michael Pavy

Meta Tag

Speaker Michael Pavy

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

observational study

progression-free survival

EGFR mutant NSCLC

Osimertinib

exon 19 deletion

exon 21 L858R mutations

tyrosine kinase inhibitors

PDL mutations

genetic profiles

personalized medicine